share_log

RxSight Insider Lowered Holding By 68% During Last Year

RxSight Insider Lowered Holding By 68% During Last Year

去年,RxSight Insider 將持股量降低了68%
Simply Wall St ·  2023/11/15 08:21

Insiders were net sellers of RxSight, Inc.'s (NASDAQ:RXST ) stock during the past year. That is, insiders sold more stock than they bought.

內部人士是 RxSight, Inc. 的淨賣家。”s(納斯達克股票代碼:RXST)在過去一年的股票。也就是說,內部人士賣出的股票多於他們買入的股票。

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

儘管在長期投資方面,內幕交易並不是最重要的事情,但我們確實認爲密切關注內部人士的所作所爲是完全合乎邏輯的。

See our latest analysis for RxSight

查看我們對 RxSight 的最新分析

RxSight Insider Transactions Over The Last Year

RxSight 過去一年的內幕交易

The Independent Director, Juliet Tammenoms Bakker, made the biggest insider sale in the last 12 months. That single transaction was for US$993k worth of shares at a price of US$30.25 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$27.20. So it may not tell us anything about how insiders feel about the current share price. Juliet Tammenoms Bakker was the only individual insider to sell over the last year.

獨立董事朱麗葉·塔梅諾姆斯·巴克爾進行了過去12個月來最大的一次內幕交易。該單筆交易以每股30.25美元的價格購買了價值99.3萬美元的股票。雖然我們通常不喜歡看到內幕拋售,但更令人擔憂的是銷售是否以較低的價格進行。令人欣慰的是,此次出售的價格遠高於目前的股價,即27.20美元。因此,它可能無法告訴我們內部人士對當前股價的看法。Juliet Tammenoms Bakker是去年唯一一位賣出的個人內部人士。

Juliet Tammenoms Bakker divested 82.29k shares over the last 12 months at an average price of US$29.76. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

Juliet Tammenoms Bakker在過去12個月中剝離了82.29萬股股票,平均價格爲29.76美元。您可以在下表中看到過去一年的內幕交易(由公司和個人進行的)。點擊下圖,你可以看到每筆內幕交易的確切細節!

insider-trading-volume
NasdaqGM:RXST Insider Trading Volume November 15th 2023
納斯達克GMM:RXST 內幕交易量 2023 年 11 月 15 日

If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: insiders have been buying them).

如果你喜歡買內部人士買入而不是賣出的股票,那麼你可能會喜歡這份免費的公司名單。(提示:業內人士一直在購買它們)。

Insiders At RxSight Have Sold Stock Recently

RxSight 的內部人士最近出售了股票

The last three months saw significant insider selling at RxSight. In total, Independent Director Juliet Tammenoms Bakker sold US$2.4m worth of shares in that time, and we didn't record any purchases whatsoever. In light of this it's hard to argue that all the insiders think that the shares are a bargain.

在過去的三個月中,RxSight進行了大量的內幕拋售。在此期間,獨立董事朱麗葉·塔梅諾姆斯·巴克爾總共出售了價值240萬美元的股票,我們沒有記錄任何買入記錄。有鑑於此,很難說所有內部人士都認爲這些股票很划算。

Insider Ownership Of RxSight

RxSight 的內部所有權

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. I reckon it's a good sign if insiders own a significant number of shares in the company. RxSight insiders own about US$105m worth of shares (which is 11% of the company). This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

檢驗公司領導者與其他股東之間一致性的另一種方法是查看他們擁有多少股票。我認爲,如果內部人士擁有該公司的大量股份,那將是一個好兆頭。RxSight內部人士擁有價值約1.05億美元的股份(佔該公司的11%)。內部人士持有這種重大所有權通常會增加公司爲所有股東的利益而經營的機會。

So What Do The RxSight Insider Transactions Indicate?

那麼,RxSight 內幕交易表明了什麼?

An insider hasn't bought RxSight stock in the last three months, but there was some selling. Looking to the last twelve months, our data doesn't show any insider buying. It is good to see high insider ownership, but the insider selling leaves us cautious. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Case in point: We've spotted 3 warning signs for RxSight you should be aware of.

在過去的三個月中,有內部人士沒有購買過RxSight的股票,但有一些人賣出。展望過去的十二個月,我們的數據沒有顯示任何內幕買盤。很高興看到內幕所有權很高,但內幕拋售使我們謹慎行事。因此,這些內幕交易可以幫助我們建立有關該股的論點,但了解該公司面臨的風險也值得一試。一個很好的例子:我們已經發現了 RxSight 的 3 個警告信號,你應該注意。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,來看看這份有趣的公司的免費清單吧。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

就本文而言,內部人士是指向相關監管機構報告其交易的個人。我們目前只考慮公開市場交易和私下處置的直接利益,不包括衍生品交易或間接權益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論